English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

According to the WHO classification acute myeloid leukemia (AML) is categorized according to cytogenetic and molecular changes [1]. The subgroups with adverse, intermediate and favorable genetics were redefined and incorporated into the major factors predicting treatment-related mortality. Postremission therapy strategies are basically related to cytogenetic abnormalities; therefore for patients with favorable-risk AML repetitive cycles of high-dose cytarabine are considered superior to autologous or allogenic hematopoietic stem cell transplantation (auto- or allo-HSCT) [2, 3].

archives of medical science/archives of medical science (online)

Letter to the Editor Isolated extramedullary breast relapses in inv(16) positive and c-KIT negative acute myeloid leukemia after allogenic hematopoietic stem cell transplantation – description of two cases